#1 Clinical Trials Search in Europe

6-Fluoro-5-[4-[(5-Fluoro-2-Methyl-3-Oxo-4H-Quinoxalin-6-Yl)Methyl]Piperazin-1-Yl]-N-Methylpyridine-2-Carboxamide

AZD9574 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors, including breast, ovarian, pancreatic, and prostate cancers. This article explores the ongoing research into AZD9574’s safety, effectiveness, and potential benefits for cancer patients. The trials aim to determine the optimal dosage, understand how the drug works in the body, and assess its ability to fight cancer cells, both alone and in combination with other treatments.

Table of Contents

What is AZD9574?

AZD9574 is a new experimental drug being developed by AstraZeneca for the treatment of various advanced solid tumors[1]. Its chemical name is 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide[1]. This drug is currently in early-stage clinical trials to evaluate its safety and effectiveness in cancer patients.

How Does AZD9574 Work?

While the exact mechanism of action is not fully described in the available information, AZD9574 appears to be a type of drug called a PARP inhibitor[1]. PARP (Poly ADP-ribose polymerase) is an enzyme that helps repair damaged DNA in cells. By inhibiting PARP, AZD9574 may prevent cancer cells from repairing their DNA, leading to their death.

The drug is being studied both as a standalone treatment (monotherapy) and in combination with other anti-cancer drugs[1]. This approach allows researchers to determine if AZD9574 can enhance the effects of existing treatments.

What Conditions Does AZD9574 Treat?

AZD9574 is being investigated for the treatment of several types of advanced solid tumors, including:

  • Breast cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Glioma (a type of brain tumor)
  • Non-small cell lung cancer (NSCLC)
  • Endometrial cancer

The drug is particularly being studied in patients with specific genetic mutations, such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D[1]. These mutations affect the body’s ability to repair DNA damage, which may make the tumors more susceptible to PARP inhibitors like AZD9574.

Current Research

AZD9574 is currently being studied in a Phase I/IIa clinical trial[1]. This type of trial is designed to:

  1. Determine the safety and tolerability of the drug
  2. Find the right dose to use in future studies
  3. Get early information about how well the drug works against cancer

The trial is divided into several modules, each focusing on different aspects of the drug’s performance:

  • Module 1: Testing AZD9574 alone (monotherapy)
  • Module 2: Combining AZD9574 with temozolomide (another cancer drug)
  • Module 3: Using special imaging (PET scans) to see how the drug affects tumors
  • Module 4: Combining AZD9574 with trastuzumab deruxtecan (for certain types of breast cancer)
  • Module 5: Combining AZD9574 with datopotamab deruxtecan

Potential Benefits

While it’s too early to know for sure how effective AZD9574 will be, researchers are hoping to see several potential benefits:

  • Shrinkage of tumors or slowing of tumor growth
  • Improved survival rates for patients with advanced cancers
  • A new treatment option for patients who have not responded to other therapies
  • Possible enhancement of the effects of other cancer drugs when used in combination

Side Effects and Safety

As AZD9574 is still in early-stage trials, its full safety profile is not yet known. The current study is designed to carefully monitor for any side effects or safety concerns[1]. Some potential side effects being watched for include:

  • Changes in blood cell counts
  • Fatigue
  • Nausea and vomiting
  • Changes in heart rhythm
  • Lung problems (when combined with certain other drugs)

It’s important to note that not all patients will experience these side effects, and the research team is working to find the safest and most effective dose of the drug.

Conclusion

AZD9574 represents a promising new approach in the fight against advanced solid tumors. While still in the early stages of research, this drug offers hope for patients with difficult-to-treat cancers, especially those with specific genetic mutations. As the clinical trial progresses, we will learn more about the effectiveness and safety of AZD9574, potentially leading to a new treatment option for cancer patients in the future.

Aspect Details
Drug Name AZD9574
Drug Type Oral film-coated tablet
Target Cancers Advanced solid tumors (breast, ovarian, pancreatic, prostate, glioma)
Trial Phase Phase I/IIa (first in human)
Main Objectives Assess safety, tolerability, pharmacokinetics, and preliminary efficacy
Study Design Multi-module, open-label, dose escalation and expansion
Combination Therapies Temozolomide, Trastuzumab deruxtecan, Datopotamab deruxtecan
Key Endpoints Adverse events, maximum tolerated dose, tumor response, biomarker changes

FAQ

  • What types of cancer is AZD9574 being tested for? AZD9574 is being tested for various advanced solid tumors, including breast, ovarian, pancreatic, prostate, and glioma (brain tumor). It's also being studied in patients with specific genetic mutations like BRCA1, BRCA2, PALB2, RAD51C, and RAD51D.
  • How is AZD9574 administered to patients? AZD9574 is given orally as a film-coated tablet. Patients take the medication by mouth as directed by their healthcare provider.
  • What are the main goals of the AZD9574 clinical trials? The main goals are to assess the safety and tolerability of AZD9574, determine the best dosage, understand how the drug behaves in the body (pharmacokinetics), and evaluate its preliminary effectiveness in fighting cancer cells.
  • Is AZD9574 being tested alone or with other treatments? AZD9574 is being tested both as a standalone treatment (monotherapy) and in combination with other anti-cancer agents, such as temozolomide, trastuzumab deruxtecan, and datopotamab deruxtecan.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial module, but generally includes adults (18 years or older) with advanced solid tumors who have specific genetic mutations or cancer types. Participants must meet certain health criteria and have adequate organ function. It's best to consult with your oncologist about specific eligibility requirements.

Ongoing Clinical Trials on 6-Fluoro-5-[4-[(5-Fluoro-2-Methyl-3-Oxo-4H-Quinoxalin-6-Yl)Methyl]Piperazin-1-Yl]-N-Methylpyridine-2-Carboxamide

  • A study testing the safety and effectiveness of AZD0516 alone and with other cancer drugs in adults with metastatic prostate cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    2 1 1 1
    Investigated drugs:
    Spain Sweden

Glossary

  • Advanced solid tumors: Cancers that have spread beyond their original site to other parts of the body, forming solid masses of cancer cells.
  • Monotherapy: Treatment using a single drug or method, as opposed to combination therapy which uses multiple treatments.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • BRCA1/BRCA2 mutations: Genetic changes in the BRCA1 or BRCA2 genes that increase the risk of certain cancers, particularly breast and ovarian cancer.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Biomarker: A measurable substance in the body that can indicate the presence of disease, infection, or environmental exposure.
  • pH2AX: A biomarker used to measure DNA damage and repair in cells, often used to assess the effectiveness of cancer treatments.

References

  1. http://clinicaltrials.eu/trial/study-of-azd9574-and-temozolomide-for-patients-with-advanced-solid-tumors-including-breast-ovarian-pancreatic-and-prostate-cancers/